Azitra (AZTR) Stock: Buy, Sell, or Hold?
AZTR - Azitra Inc
$0.07
-0.05 (-39.20%)
▼
5d:
-45.0%
30d:
-59.26%
90d:
-47.08%
WAIT
LOW Confidence
Analysis Updated: Oct 13, 2026 12:00 AM ET
Earnings: Nov 11, 2026
17d
Get Alerted When AZTR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AZTR is down 45.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AZTR is down 45.0% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AZTR is currently trading at $0.07, which is considered oversold relative to its 30-day fair value range of $0.12 to $0.17.
Technical Outlook: Technically, AZTR is in a downtrend. Immediate support is located at $0.05, while resistance sits at $0.15. Short-term momentum is weak, with the stock down 39.2% recently.
Market Sentiment: AZTR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $0.67 (+837.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AZTR is in a downtrend. Immediate support is located at $0.05, while resistance sits at $0.15. Short-term momentum is weak, with the stock down 39.2% recently.
Market Sentiment: AZTR scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $0.67 (+837.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.12 -
$0.17
Company Quality Score
42/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-39.2%)
- BULLISH: Trading 837.1% below Wall St target ($0.67)
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.12 -
$0.17
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.05
Resistance Level
$0.15
Current Trend
Downtrend
Technical data as of
Oct 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.75
Wall Street Target
$0.67
(+837.1%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 23, 2026 7:32 PM ET
Data refreshes hourly during market hours. Next update: 8:32 PM
Data refreshes hourly during market hours. Next update: 8:32 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AZTR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
28 analysts |
$92 | 73 BUY |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
23 analysts |
$108 | 58 HOLD |
|
SRRK
Scholar Rock Holding Corp |
STRONG BUY
18 analysts |
$70 | 72 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
20 analysts |
$36 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
22 analysts |
$283 | 43 HOLD |
